iOnctura’s roginolisib awarded Innovation Passport
MHRA designation involves entry into innovative licensing and access pathway
Read More
Tag: roginolisib
iOnctura reveals roginolisib research results
Therapy prevents tumour proliferation while breaking immune tolerance among cancer patients
Read More
- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
- Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage
- Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
- MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
